Compounds > dmp 850
Page last updated: 2024-12-08

dmp 850

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

DMP 850: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID470550
CHEMBL ID346818
SCHEMBL ID13538413
MeSH IDM0299175

Synonyms (10)

Synonym
dmp-850
(5s,6s,4r,7r)-1-[(3-amino(1h-indazol-5-yl))methyl]-5,6-dihydroxy-3,4,7-trisbenzyl-1,3-diazaperhydroepin-2-one
dmp 850
(4r,5s,6s,7r)-1-[(3-amino-1h-indazol-5-yl)methyl]-3,4,7-tribenzyl-5,6-dihydroxy-1,3-diazepan-2-one
(4r,5s,6s,7r)-1-(3-amino-1h-indazol-5-ylmethyl)-3,4,7-tribenzyl-5,6-dihydroxy-[1,3]diazepan-2-one
bdbm50124721
CHEMBL346818 ,
bdbm36646
dmp850
SCHEMBL13538413

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" The ultimate success of DMP 850 and DMP 851 in clinical trials might depend on achieving or exceeding the oral bioavailability seen in dog."( Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors.
Anderson, PS; Bacheler, LT; Chang, CH; Cordova, B; Erickson-Viitanen, S; Garber, S; Johnson, BL; Klabe, RM; Ko, SS; Lam, PY; Li, R; Reid, C; Rodgers, JD; Ru, Y; Seitz, SP; Trainor, GL; Wang, H; Wright, MR, 1998)		0.91

Dosage Studied

ExcerptRelevanceReference
" While the use of currently approved HIV protease inhibitors in concert with drugs that target the reverse transcriptase has dramatically ameliorated the disease state for many individuals, highly-structured dosing regimens accompanied by adverse side-effect profiles have led to a significant level of patient non-compliance."( Non-peptidic HIV protease inhibitors.
Chrusciel, RA; Strohbach, JW, 2004)		0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gag polyproteinHIV-1 M:B_MNIC50 (µMol)0.04900.01300.02380.0490AID1799450
Protease Human immunodeficiency virus 1Ki0.00000.00000.04433.1000AID160279
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID160279Binding affinity against HIV-Protease was determined2003Bioorganic & medicinal chemistry letters, Feb-24, Volume: 13, Issue:4
Synthesis, antiviral activity and pharmacokinetics of P1/P1' substituted 3-aminoindazole cyclic urea HIV protease inhibitors.
AID92064Protein binding adjusted IC90s for the I84V mutant was determined2003Bioorganic & medicinal chemistry letters, Feb-24, Volume: 13, Issue:4
Synthesis, antiviral activity and pharmacokinetics of P1/P1' substituted 3-aminoindazole cyclic urea HIV protease inhibitors.
AID85148 hour trough Blood level in dog was measured after administration of compound2003Bioorganic & medicinal chemistry letters, Feb-24, Volume: 13, Issue:4
Synthesis, antiviral activity and pharmacokinetics of P1/P1' substituted 3-aminoindazole cyclic urea HIV protease inhibitors.
AID9096Pharmacokinetic activity (Cmax) in dog2003Bioorganic & medicinal chemistry letters, Feb-24, Volume: 13, Issue:4
Synthesis, antiviral activity and pharmacokinetics of P1/P1' substituted 3-aminoindazole cyclic urea HIV protease inhibitors.
AID81780Inhibitory concentration of compound against HIV abbott mutant virus 25-fold resistant to ritonavir2003Bioorganic & medicinal chemistry letters, Feb-24, Volume: 13, Issue:4
Synthesis, antiviral activity and pharmacokinetics of P1/P1' substituted 3-aminoindazole cyclic urea HIV protease inhibitors.
AID105001Inhibitory concentration of compound against HIV 184V mutant in MT2 cells2003Bioorganic & medicinal chemistry letters, Feb-24, Volume: 13, Issue:4
Synthesis, antiviral activity and pharmacokinetics of P1/P1' substituted 3-aminoindazole cyclic urea HIV protease inhibitors.
AID92063Effect on increase in RNA IC90 value after HSA (45 mg/mL) and AAG (1 mg/mL) were determined in absence or presence of two plasma proteins (45 mg/mL human serum albumin and 1 mg/mL alpha-1-acid glycoprotein).2003Bioorganic & medicinal chemistry letters, Feb-24, Volume: 13, Issue:4
Synthesis, antiviral activity and pharmacokinetics of P1/P1' substituted 3-aminoindazole cyclic urea HIV protease inhibitors.
AID81779Inhibitory concentration of compound against HIV HXB2 strain2003Bioorganic & medicinal chemistry letters, Feb-24, Volume: 13, Issue:4
Synthesis, antiviral activity and pharmacokinetics of P1/P1' substituted 3-aminoindazole cyclic urea HIV protease inhibitors.
AID105002Inhibitory concentration of compound against HIV V82F/184V mutant in MT2 cells2003Bioorganic & medicinal chemistry letters, Feb-24, Volume: 13, Issue:4
Synthesis, antiviral activity and pharmacokinetics of P1/P1' substituted 3-aminoindazole cyclic urea HIV protease inhibitors.
AID9705Half life period (10 mg/kg) was determined in dog2003Bioorganic & medicinal chemistry letters, Feb-24, Volume: 13, Issue:4
Synthesis, antiviral activity and pharmacokinetics of P1/P1' substituted 3-aminoindazole cyclic urea HIV protease inhibitors.
AID9354Oral bioavailability in dog (dose 10 mg/kg)2003Bioorganic & medicinal chemistry letters, Feb-24, Volume: 13, Issue:4
Synthesis, antiviral activity and pharmacokinetics of P1/P1' substituted 3-aminoindazole cyclic urea HIV protease inhibitors.
AID81781Inhibitory concentration of compound against HIV vertex mutant virus 19-fold resistant to amprenavir2003Bioorganic & medicinal chemistry letters, Feb-24, Volume: 13, Issue:4
Synthesis, antiviral activity and pharmacokinetics of P1/P1' substituted 3-aminoindazole cyclic urea HIV protease inhibitors.
AID81784Resistance factor of compound towards HIV-1 was measured as inhibitory concentration of compound required to inhibit viral RNA transcripts accumulation after infection in cells2003Bioorganic & medicinal chemistry letters, Feb-24, Volume: 13, Issue:4
Synthesis, antiviral activity and pharmacokinetics of P1/P1' substituted 3-aminoindazole cyclic urea HIV protease inhibitors.
AID1799449Protease Inhibtion Assay from Article 10.1016/s1074-5521(98)90117-x: \\Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors.\\1998Chemistry & biology, Oct, Volume: 5, Issue:10
Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors.
AID1799450Enzyme Inhibtion Assay from Article 10.1016/s1074-5521(98)90117-x: \\Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors.\\1998Chemistry & biology, Oct, Volume: 5, Issue:10
Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's4 (80.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.66 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (40.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other3 (60.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
carbamates
[no description available]		210amino-acid anion
urea
pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.		9.7250isourea;
monocarboxylic acid amide;
one-carbon compound		Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
dimethylacetamide
hallucinogen : Drugs capable of inducing illusions, hallucinations, delusions, paranoid ideations and other alterations of mood and thinking.. N,N-dimethylacetamide : A member of the class of acetamides that is acetamide in which the hydrogens attached to the N atom have been replaced by two methyl groups respectively. Metabolite observed in cancer metabolism.		210acetamides;
monocarboxylic acid amide		human metabolite
nelfinavir
Nelfinavir: A potent HIV protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children.. nelfinavir : An aryl sulfide that is used (as its mesylate salt) for treatment of HIV and also exhibits some anticancer properties.		2.420aryl sulfide;
benzamides;
organic heterobicyclic compound;
phenols;
secondary alcohol;
tertiary amino compound		antineoplastic agent;
HIV protease inhibitor
amprenavir
[no description available]		2.420carbamate ester;
sulfonamide;
tetrahydrofuryl ester		antiviral drug;
HIV protease inhibitor
dmp 323
(4R,5S,6S,7R)-4,7-dibenzyl-5,6-dihydroxy-1,3-bis[4-(hydroxymethyl)benzyl]-1,3-diazepan-2-one : A 1,3-diazepanone ring with two 4-(hydroxymethyl)benzyl groups as substituents at positions N-1 and N-4, two benzyl groups at C-4 and C-7, and two hydroxy groups at C-5 and C-6 respectively.		1.9910diazepanone;
ureas		anti-HIV agent;
metabolite
dmp 450
DMP 450: structure in first source		2.420
atazanavir sulfate
Atazanavir Sulfate: An azapeptide and HIV-PROTEASE INHIBITOR that is used in the treatment of HIV INFECTIONS and AIDS in combination with other ANTI-HIV AGENTS.		3.1210organic sulfate salt
ritonavir
Ritonavir: An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A.. ritonavir : An L-valine derivative that is L-valinamide in which alpha-amino group has been acylated by a [(2-isopropyl-1,3-thiazol-4-yl)methyl]methylcarbamoyl group and in which a hydrogen of the carboxamide amino group has been replaced by a (2R,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl group. A CYP3A inhibitor and antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.		2.4201,3-thiazoles;
carbamate ester;
carboxamide;
L-valine derivative;
ureas		antiviral drug;
environmental contaminant;
HIV protease inhibitor;
xenobiotic
saquinavir
Saquinavir: An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases, and also inhibits CYTOCHROME P-450 CYP3A.. saquinavir : An aspartic acid derivative obtained by formal condensation of the primary amino group of (2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl]-3-hydroxy-1-phenylbutan-2-ylamine with the carboxy group of N(2)(-quinolin-2-ylcarbonyl)-L-asparagine. An inhibitor of HIV-1 protease.		3.5120L-asparagine derivative;
quinolines		antiviral drug;
HIV protease inhibitor
tetronic acid
tetronic acid: structure; in fifth source		3.1210
indinavir sulfate
Indinavir: A potent and specific HIV protease inhibitor that appears to have good oral bioavailability.		2.420dicarboxylic acid diamide;
N-(2-hydroxyethyl)piperazine;
piperazinecarboxamide		HIV protease inhibitor
tipranavir
tipranavir: inhibits HIV-1 protease. tipranavir : A pyridine-2-sulfonamide substituted at C-5 by a trifluoromethyl group and at the sulfonamide nitrogen by a dihydropyrone-containing m-tolyl substituent. It is an HIV-1 protease inhibitor.		3.1210sulfonamideantiviral drug;
HIV protease inhibitor
pd 178390
PD 178390: structure in first source		3.1210
pnu 103017
PNU 103017: an HIV aspartyl protease inhibitor; structure in first source		3.1210
ConditionIndicatedRelationship StrengthStudiesTrials
HIV
Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.		08.6230
HIV Coinfection
[description not available]		02.9310
HIV Infections
Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).		02.9310